Core Insights - Ningbo Meinuo Pharmaceutical Co., Ltd. and Zhejiang Shengzhao Pharmaceutical Technology Co., Ltd. have signed a strategic cooperation agreement to collaborate in the complex injection drug sector, aiming to leverage their respective strengths in R&D, production, registration, and commercialization [1] Group 1: Industry Positioning - Shengzhao Pharmaceutical focuses on the "complex injection" field, which includes high-tech barrier injection types such as microspheres, liposomes, and microcrystals, essential for treating chronic diseases like mental disorders and cancer [2] - The complex injection market has been dominated by a few multinational pharmaceutical companies due to high R&D difficulty and strict quality control, leading to high patient costs and low domestic production [2] Group 2: Core Advantages of Shengzhao Pharmaceutical - Shengzhao has established a comprehensive technology platform covering mainstream complex injection types, enabling parallel development of multiple high-difficulty products [3] - The company boasts a strong R&D team with international experience, which has accumulated deep technical expertise in formulation processes and quality control, effectively reducing R&D risks [3] - Shengzhao has achieved significant breakthroughs in the industrialization of complex injections, with its core product, a risperidone microsphere injection, being the first generic approved for market, demonstrating its capability to transition from lab to production [3] - The company has a rich product pipeline addressing urgent clinical needs across various therapeutic areas, ensuring long-term competitive advantages [3] Group 3: Cooperation Outlook - The agreement allows Meinuo to utilize its strengths in chemical raw materials, GMP-compliant production, and global registration, while Shengzhao will provide key technical support for complex injection product development [4] - This collaboration is expected to help both companies seize market opportunities in complex injections and promote the overall development of China's high-end formulation industry, ultimately benefiting patients with more accessible domestic high-end drugs [4]

Core Insights - Meinuohua's stock price increased by 2.02% on October 14, reaching 22.27 CNY per share, with a total market capitalization of 4.913 billion CNY [1] - The company has seen a year-to-date stock price increase of 75.91%, but a decline of 13.41% over the past 20 days [1] Financial Performance - For the first half of 2025, Meinuohua reported revenue of 677 million CNY, representing a year-on-year growth of 11.42%, and a net profit attributable to shareholders of 49.06 million CNY, up 158.97% [2] - Cumulative cash dividends since the company's A-share listing amount to 149 million CNY, with 50.58 million CNY distributed over the past three years [3] Shareholder Information - As of June 30, 2025, Meinuohua had 32,400 shareholders, an increase of 17.14% from the previous period, with an average of 6,590 circulating shares per shareholder, down 14.63% [2] - Notable changes in institutional holdings include the exit of several funds from the top ten circulating shareholders [3]

Core Viewpoint - Meihua (603538) has officially signed a strategic cooperation agreement with Zhejiang Shengzhao Pharmaceutical Technology Co., Ltd. to collaborate in technology development, production and supply chain, market expansion, and commercialization [1] Group 1 - The strategic cooperation agreement aims to enhance collaboration in technology development and transformation [1] - The partnership will focus on production and supply chain improvements [1] - Market expansion and commercialization efforts will be a key area of collaboration [1]

Group 1 - The company announced that its convertible bond, "Meinuo Convertible Bond," is expected to meet the conditions for a downward adjustment of the conversion price [1][6] - The initial conversion price was set at 37.47 yuan per share, with subsequent adjustments made due to stock incentive plans and annual profit distributions [2][3][4] - As of September 30, 2025, a total of 43,599,000 yuan of "Meinuo Convertible Bond" has been converted into company shares, representing 0.788% of the total shares issued before the conversion [12][17] Group 2 - The company has outlined the conditions under which the conversion price can be adjusted downward, specifically if the stock price falls below 90% of the current conversion price for at least 15 out of 30 consecutive trading days [6][8] - The current conversion price is 25.68 yuan per share, and if the stock price falls below 23.11 yuan for five trading days within the next twenty days, it may trigger a downward adjustment [8] - The company will disclose any decisions regarding the adjustment of the conversion price through official announcements [7][8]

| | | 宁波美诺华药业股份有限公司 关于"美诺转债"预计满足转股价格向下修正条件的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、可转换公司债券基本情况 （一）可转换公司债券发行上市概况 经中国证券监督管理委员会《关于核准宁波美诺华药业股份有限公司公开发 行可转换公司债券的批复》（证监许可[2020]2377 号）核准，2021 年 1 月 14 日， 宁波美诺华药业股份有限公司（以下简称"公司"）公开发行 52,000 万元可转换 公司债券，共发行 520 万张，每张面值 100 元，期限 6 年。2021 年 2 月 4 日起， 上述可转换公司债券在上海证券交易所挂牌交易，转债简称"美诺转债"，转债 代码"113618"。 "美诺转债"存续的起止日期为 2021 年 1 月 14 日至 2027 年 1 月 13 日，转 股期起止日期为 2021 年 7 月 20 日至 2027 年 1 月 13 日，初始转股价格为 37.47 元/股。 （二）可转换公司债券转股价格历次调整情况 1、2021 年 12 ...

重要内容提示： 累计转股情况：截至 2025 年 9 月 30 日，累计共有人民币 43,599,000 元"美诺转债"已转换为公司股票，转股数量为 1,178,613 股，占可转债开始转 股前公司已发行股份总额的 0.788%。 | 证券代码：603538 | 证券简称：美诺华 | 公告编号：2025-100 | | --- | --- | --- | | 转债代码：113618 | 转债简称：美诺转债 | | 宁波美诺华药业股份有限公司 可转债转股结果暨股份变动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 未转股可转债情况：截至 2025 年 9 月 30 日，尚未转股的可转债金额为 人民币 476,401,000 元，占可转债发行总量的 91.616%。 本季度转股情况：自 2025 年 7 月 1 日至 2025 年 9 月 30 日期间，转股的 金额为 121,000 元，因转股形成的股份数量为 4,703 股。 一、可转债发行上市概况 （一） 经中国证券监督管理委员会《关于核准宁波美诺华药业股份有限公 司公 ...

| | | 宁波美诺华药业股份有限公司 关于 2021 年股票期权与限制性股票激励计划 2025 年第三季度 自主行权结果暨股份变动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 本季度行权股票数量：自 2025 年 7 月 1 日至 2025 年 9 月 30 日期间，首 次授予股票期权第三个行权期累计行权 508,389 股，占首次授予股票期权第三个 行权期可行权总量的 25.72%。预留授予股票期权第二个行权期累计行权 276,530 股，占预留授予股票期权第二个行权期可行权总量的 37.45%。 本次行权股票上市流通时间：首次授予股票期权第三个行权期行权方式、 预留授予股票期权第二个行权期行权方式均为自主行权，首次授予股票期权第三 个行权期为 2025 年 1 月 17 日至 2025 年 12 月 29 日，预留授予股票期权第二个 行权期为 2024 年 12 月 25 日至 2025 年 11 月 24 日。 一、本次股票期权行权的决策程序及相关信息披露 1、2021 年 11 月 18 日，公司召开第四届董 ...

Group 1 - The core viewpoint is that Meinohua (603538.SH) is currently discussing the development of a hangover relief product as an alternative offering with its partners [1] Group 2 - The company is actively engaging with partners regarding the potential of the hangover relief product [1]

上海市广发律师事务所 关于宁波美诺华药业股份有限公司 2025 年第一次临时股东大会的 法律意见书 电话：021-58358013 | 传真：021-58358012 网址：http://www.gffirm.com | 电子信箱：gf@gffirm.com 办公地址：上海市浦东新区南泉北路 429 号泰康保险大厦 26 楼 | 邮政编码：200120 上海市广发律师事务所 关于宁波美诺华药业股份有限公司 2025 年第一次临时股东大会的法律意见书 致：宁波美诺华药业股份有限公司 宁波美诺华药业股份有限公司（以下简称"公司"）2025 年第一次临时股 东大会于 2025 年 9 月 11 日在浙江省宁波市高新区扬帆路 999 弄研发园 B1 号楼 12A 层 1 号会议室召开。上海市广发律师事务所经公司聘请，委派姚培琪律师、 王俊峰律师出席现场会议。根据《中华人民共和国公司法》（以下简称"《公司 法》"）、《上市公司股东会规则》（以下简称"《股东会规则》"）等法律法 规、其他规范性文件以及《宁波美诺华药业股份有限公司章程》（以下简称"《公 司章程》"）的规定，就本次股东大会的召集和召开程序、召集人及出席会议人 ...

| 证券代码：603538 | 证券简称：美诺华 | 公告编号：2025-099 | | --- | --- | --- | | 转债代码：113618 | 转债简称：美诺转债 | | 宁波美诺华药业股份有限公司 2025年第一次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 （二）股东大会召开的地点：浙江省宁波市高新区扬帆路 999 弄研发园 B1 号楼 12A 层 1 号会议室。 （三）出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 357 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 60,389,820 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | 27.3737 | | 份总数的比例（%） | | （四）表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次股东大会由公司董事会召集，公司董事长姚成志先生主持会议。会议采 ...